Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen
Alligator Bioscience announced that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc.
The milestone payment is for the partnership agreement to initiate a clinical combination study of ADC-1013 with one of Janssen's proprietary PD-1 inhibitors. This is the first out of a number of pre-defined milestones, related to the start of combination or phase II studies as part of the ADC-1013 clinical program, which all together have an aggregated potential value of 35 MUSD.
The licensing agreement with Janssen Biotech Inc. encompasses milestone payments up to a potential total value of USD 695 million. Alligator is also eligible to receive tiered royalties on worldwide net sales upon successful launch and commercialization of ADC-1013.
"We are pleased that our collaboration with Janssen is continuing to progress according to plan", said Per Norlén, CEO at Alligator Bioscience. "The upcoming combination is a very important step in the continued clinical development. Synergy between ADC-1013 and PD-1 blocking antibodies is supported by pre-clinical data. If this translates to the clinic, it could create new treatment opportunities for many cancer patients".
Alligator's partner Janssen Biotech, Inc. is performing a phase I dose-escalation clinical study (ClinicalTrials: NCT02829099) with intravenous administration of JNJ-64457107 (ADC-1013). This study is ongoing with approximately 50 patients recruited to date.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Study shows how bioactive substance inhibits important receptor - Results from the University of Bonn raise hope for new drugs against cancer and brain diseases

With mini-vessels, mini-brains expand research potential

Scientists engineer new potent antibiotic - Darobactin 22 could have the potential to become the next antibiotic superstar

How biofuels from plant fibers could combat global warming

DNA Chips as Storage Media of the Future

Tiny “blinkers” reveal molecules inside cells

BASF lifts force majeure for key vitamin A and E products

Images of NMDA receptors help explain how they are affected by zinc and a drug

Scientists seek to engineer chatter among cells
